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Abstract
Abnormal insoluble ubiqitinated protein aggregates are found in the brains of Huntington’s disease (HD) patients and in
mice transgenic for the HTT mutation. Here, we describe the earliest stages of visible NII formation in brains of R6/2 mice
killed between 2 and 6 weeks of age. We found that huntingtin-positive aggregates formed rapidly (within 24–48 hours) in
a spatiotemporal manner similar to that we described previously for ubiquitinated inclusions. However, in most neurons,
aggregates are not ubiquitinated when they first form. It has always been assumed that mutant huntingtin is recognised as
‘foreign’ and consequently ubiquitinated and targeted for degradation by the ubiquitin-proteasome system pathway. Our
data, however, suggest that aggregation and ubiquitination are separate processes, and that mutant huntingtin fragment is
not recognized as ‘abnormal’ by the ubiquitin-proteasome system before aggregation. Rather, mutant Htt appears to
aggregate before it is ubiquitinated, and then either aggregated huntingtin is ubiquitinated or ubiquitinated proteins are
recruited into aggregates. Our findings have significant implications for the role of the ubiquitin-proteasome system in the
formation of aggregates, as they suggest that this system is not involved until after the first aggregates form.
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Introduction
Huntington’s disease (HD) is one of a family of progressive genetic
neurodegenerativedisorders causedby thepathological expansionof
a CAG repeat in the HTT disease gene that encodes the protein
huntingtin (Htt) [1]. The mechanism by which the CAG repeat
expansion causes HD is not known. However, the discovery of
neuronal intranuclear inclusions (NIIs) in the brains of mice
transgenic for a protein fragment carrying the HTT mutation [2]
and subsequently in brains ofHDpatients [2,3] has triggered a great
deal of interest in both the mechanisms of inclusion formation and
their potentially pathogenic role. The importance of inclusion
pathology is not restricted to HD, since inclusions are present in
brains of patients with other polyglutamine diseases and all mouse
models thus farexamined (forreview,see[5]).Nevertheless, theroleof
inclusions in HD pathology is not only unclear, but is also hotly
debated (for review see [6]). There is evidence suggesting that they
may be neurotoxic ([7,8,9,10,11,12,13,14], neuroprotective
[15,16,17,18,19,20,21,22,23,24] or both, depending on when and
where they form [25,22].
Despite the debate about their role, there is no doubt that
inclusions are a clear histopathological marker of the disease [26].
Inclusions are not found in neurologically normal subjects, but are
found throughout the HD brain, particularly in striatum (STR)
and cortex (CTX), the brain regions most affected in HD
[3,4,16,27,28]. NIIs are defined as abnormal ubiquitinated
aggregates of proteins, predominantly huntingtin and/or frag-
ments of huntingtin and ubiquitin, although a number of other
proteins have been found associated with inclusions in transgenic
mouse and cell models [29,30] and human brains [31].
Importantly, it has always been assumed that mutant huntingtin
is recognised as ‘foreign’ and consequently ubiquitinated and
targeted for degradation by the ubiquitin-proteasome system
pathway, because (1) a mutation in the gene coding for huntingtin
causes HD, (2) mutant huntingtin is found in neuronal intra-
nuclear inclusions, (3) neuronal nuclear inclusions are ubiquiti-
nated, (4) the ubiquitin-proteasome pathway is responsible for
recognising and disposing of abnormal proteins and (5) protea-
some fragments are associated with NIIs.
To understand the role of NIIs in HD pathology, it would help
if we knew what relationship exists between the appearance of
inclusions, their ubiquitination and the onset of neuronal
dysfunction. Here, we focused on the first stage of inclusion
formation. We used juvenile R6/2 mice to study ex vivo the
processes of Htt aggregation and inclusion formation. R6/2 mice
show progressive neurological impairments [32,33,34,35] and the
appearance of ubiquitinated inclusions precedes the appearance of
measurable behavioral (motor and cognitive) phenotypic changes
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[25] and happens at around the same time as abnormalities in
synaptic plasticity [36] and early changes in brain markers [37] are
first seen.
We performed an extensive and comparative immunohisto-
chemical analysis of Htt aggregation and inclusion ubiquitination
to pinpoint both the order of appearance and the regional location
of aggregates in R6/2 brain. For this, we used the MW8 antibody
that is specific for the aggregated conformation of mutant Htt
protein [38], along with anti-ubiquitin antibodies. We showed that
visible Htt-immunopositive aggregates are present in R6/2 brain
as early as 2 weeks of age and appear in a region specific manner
throughout the brain over the next few weeks. Notably, individual
Htt-positive aggregates formed very rapidly, within the interval of
a single day in most brain regions. Our data suggest that mutant
Htt aggregation occurs rapidly and is then either ubiquitinated or




Mice were taken from a colony of R6/2 mice established in the
Department of Pharmacology, University of Cambridge, as
previously described [33]. The line was maintained by back-
crossing transgenic males onto female CBA6C57BL/6 F1 mice.
All mice used in this study were taken from the 21st and the 23rd
generations of back-crosses. The CAG repeat lengths of transgenic
mice used were measured and the mean repeat length was
calculated as 18861 (N= 122; see genotyping section for more
information). All mice were housed with a 12-hour light/dark
cycle in a temperature- and humidity-controlled environment.
Food (mash and dry food) and water were available ad libitum.
Mice used for the earliest time-points (4 weeks of age and
younger) were not weaned. Older mice were weaned, separated by
gender and housed in groups of mixed genotype at 4 weeks.
Time-Course Tissue Collection Scheme
We wanted to ensure that for all time-points we had at least 3
animals of each genotype from three different litters, and that for
each animal we had one littermate that was exactly 24 hours
younger and one that was 24 hours older (except for the 14 day
timepoint where we only needed an older littermate). For time-
course time-points between 14 and 28 days of age, brain tissue was
collected at intervals of 24 hours. This interval was chosen because
in vitro, aggregation is observed within this timeframe. Since most
of the early time-course time-points used in this study preceded the
age at which we were able to take samples for genotyping (2.5–3
weeks of age), a tissue collection ‘scheme’ was used for mice up to
25 days as follows. We used only litters that contained 9–12 pups.
We did not distinguish between the sexes. Three or four mice were
randomly selected from each litter to be killed at the same time of
day on each of 3 consecutive days. Thus, any given mouse, on any
given day, had at least one WT and one R6/2 littermate killed 24
hours before or 24 hours after it had been killed. This allowed us
to compare regional appearance of inclusions in littermates at 24
hourly intervals. Performing the time-course in this way allowed us
to examine variability between animals killed at specific time-
points as well as between littermates exactly 24 hours apart. R6/2
and WT mice killed at ages greater than 25 days (4, 5, 6, 9 and 12
weeks) were killed according to their genotypes (N= 4 R6/2 and 3
WT littermates at each age).
Animals were genotyped to ascertain the distribution of R6/2
and WT within these groups. We used 12 litters (122 mice) for
tissue collection for time course points up to 25 days, and a total of
35 mice for the other time points. All brains were dissected, frozen
on powdered dry ice and stored at 280uC until use as previously
described (Morton et al., 2000).
Genotyping
Genotyping was performed by PCR from tail snips taken at 3
weeks of age and CAG repeat lengths were measured by Laragen
(USA). All CAG repeat numbers reported are those determined
directly by Genemapper software (note that the CAG repeat
number measured by GeneMapper differs from that measured by
sequencing). To convert the CAG repeat numbers determined by
GeneMapper technique to the CAG repeat number determined
by sequencing technique (which more closely represents the true
CAG repeat number) the following formula needs to be applied:
SEQ CAG no. (true CAG no.) = 1.0427 * GM CAG no. +1.1695;
personal communication, Dr J. Li, Laragen).
Immunohistochemistry
The antibody staining procedure was performed essentially as
previously described [25]. Antibodies used were either a rabbit
polyclonal antibody raised against poly-ubiquitin (1:2000; Dako,
Denmark) or a mouse monoclonal antibody MW8 raised against
Htt (1:2000; kind gift of Dr. Paul Patterson, Caltech, CA, USA).
The MW panel of antibodies was raised against synthetic peptides
of polyglutamine disease protein fragments with expanded repeats
[38]. MW8 was raised against the first exon of mutant Htt with
antigenic boosts of aggregated Htt protein [38]. MW8 recognises
the aggregated conformation of mutant Htt, and epitope-mapping
studies reveal that it recognises the C-terminal portion of exon 1,
specifically the sequence AVAEEPLHRPK [38]. This sequence
shows no known homology to any protein other than Htt (BLAST
searches). MW8 has been reported to label nuclear inclusions in
R6/2 brain exclusively (although in our hands it also stains
neuropil aggregates, see below). It shows no staining above
background in WT animals (this study; [38]). Horseradish
peroxidase (HRP)-conjugated secondary antibodies were used to
label bound primary antibodies (1:2000; Vector, Peterborough,
UK). Importantly, the MW8 staining here was obtained with
standard histological techniques and without assistance from
antigen retrieval methods that are required to ‘reveal’ aggregates
that were not seen before (e.g. formic acid treatment [39,40]).
Cryosections of fresh frozen R6/2 and WT brain tissue were cut
at 30 mm thickness onto gelatin-coated glass slides and processed
for immunohistochemical staining. Sections were peroxidase-
inactivated for 15 min at room temperature (20% v/v methanol,
0.2% Triton X-100 and 1% v/v hydrogen peroxide in phosphate-
buffered saline (PBS)) and incubated in block solution (3% deer
serum, 0.2% Triton X-100 and 0.1% sodium azide in PBS) for at
least 3 hours at room temperature. At least one run of staining
included sections from all of the animals used in the study and all
of the sections were incubated in the same solution. Parallel
sections were incubated with primary antibodies diluted in block
solution at 4uC for a week, extensively washed and incubated with
secondary antibodies diluted into wash solution at 4uC overnight.
We used parallel sections rather than double staining to be sure
that there was no false positives. Parallel sections allowed us to
repeat staining on negative sections. Immunoreactivity was
visualised using diaminobenzidine (Sigma, Poole, UK). All of the
staining was done in parallel, timed to within 5 seconds over a 10
minute incubation period, in the same solution. A confirmation
series of staining was done with one slide (a series of sections) from
every animal in the study developed together. A slide with parallel
sections from each brain was stained with 1% cresyl violet acetate
solution in water (CV), mounted in Histoclear (CellPath, New-
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town, UK) to aid neuroanatomical identification of brain regions.
All immunostained slides were counterstained with Hoechst 33258
dye (5 mg/ml in PBS for 30 min) to label nuclei, mounted in
glycerol jelly, covered with a coverslip and stored in the dark at
room temperature until analysis.
Light and Fluorescence Microscopy
We have shown previously that ubiquitinated NIIs appear first
in juvenile R6/2 brain in the indusium griseum (IG), where they
are visible by 3 weeks of age. Then, between 3 and 4.5 weeks of
age NIIs appear in the CA1 region of hippocampus (Hf), layers II/
III and V of frontal and parietal CTX, and STR [25]. In the
current study, we again focused on these brain regions, because
the different cell types in them are easily identified by their
anatomical location.
Slides were analysed using an inverted fluorescence Nikon
Eclipse TE-2000 microscope (Nikon, Surrey, UK). Hoechst 33342
staining of nuclei was visualised with UV light excitation and
a DAPI filter. Photomicrographs were taken at X40 and X100
(under oil immersion) objective magnification with the same time
exposure settings using the Nikon Still Camera DXM1200 and the
Nikon Lucia software system (Nikon, Surrey, UK).
Aggregates and Inclusions
In previous studies of protein aggregation in HD brain, the
terms ‘aggregate’ and ‘inclusion’ have been used interchange-
ably to identify ubiquitinated deposits of proteins in human and
mouse HD brain. This has not caused difficulties in discussions
of ‘inclusions’ for two main reasons. Firstly, ubiquitin antibody
staining is generally accepted as the benchmark marker for
identifying inclusions. Secondly, few research groups have made
detailed studies of the difference between ubiquitin-positive
inclusions and Htt-positive aggregates. However, the use of
MW8 in the course of this study showed it was possible to
clearly distinguish aggregates of Htt from aggregates with the
classical morphological appearance of ubiquitinated ‘inclusions’.
Therefore, we have used the term ‘inclusion’ only when
referring to an aggregation of protein in the nucleus that is
ubiquitinated, such as were classically described in human and
mouse HD brain [2,25]. It is also important to stress that this
study did not include microaggregate foci and focused solely on
aggregates.
Aggregated Huntingtin
For convenience, throughout this paper, we describe the
proteins that are visualised by MW8 as ‘aggregated mutant
huntingtin’. This is not strictly accurate, since the transgene
includes only the first exon of the HD gene. Thus, the major
protein species that is found in inclusions in R6/2 mice is not full
length huntingtin, but rather a mutant fragment of huntingtin with
a pathological length polyglutamine repeat.
Figure 1. Aggregate appearance in indusium griseum (IG). Htt aggregates visualised by staining with the MW8 antibody were present in
adjacent sections for IG of R6/2 brains as early as 14 days of age (A, black arrowheads) and increased in number with time (B, C; black arrowheads).
Staining with ubiquitin antibody did not reveal the presence of inclusions in any region at these time points (A’–C’). Cell distribution in this region
was visualised with a cresyl violet (CV) stain (A’’–C’’). Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g001
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Results
Htt Aggregation is a Rapid and Early Event
By comparing littermates that were killed exactly 24 hours
apart, we were able to determine the age at which Htt aggregates
first became visible at a light level. MW8-positive aggregates were
already present in the IG of R6/2 brains by 14 days of age (Fig. 1),
but were not visible in any other brain region. Thus the aggregates
in IG were used as a reliable internal positive control for the MW8
antibody staining.
In many cells, Htt aggregates that could be visualised by
staining with MW8 appeared almost overnight. For example, in
the parietal cortex, MW8-positive aggregates were absent from
all layers at 15 days (Fig. 2A, A’, D and D’). Aggregates were
present at 16 days in layer V (Fig. 2E and E’), but not in layer
II/III (Fig. 2B and B’). By 18 days aggregates were also present
in layer II/III (Fig. 2C, C’). Similarly, in CA1 cells of the
hippocampus, Htt aggregates could not be seen at 18 days of
age (data not shown) but were visible as diffuse aggregates in
many neurons at 19 days (Fig. 3B, B’ and B’’) and clearly
present by 22d (Fig. 3C, C’ and C’’).
Both the number of cells with aggregates and the levels of
immunostaining intensity varied markedly in different regions of
the same brain, suggesting that Htt aggregation is timed according
to the identity of the cell population. However, aggregate
formation appeared to follow a similar pattern in neurons of
a single class. For example in pyramidal cells in the CA1 region of
the hippocampus, MW8-positive aggregates first appeared with
a diffuse morphology on day 19 (Fig. 3 and Fig. 4). Over the next
few days, the Htt aggregates changed from being amorphous to
having clear nucleation centres that became visible at 22 days
(Fig. 3 and Fig. 4). This pattern was typical of all CA1 neurons. By
contrast, in the dentate gyrus (DG) of the hippocampus Htt
aggregates were first seen at 26 days (Fig. 3, Fig. 4), many days
after they were first observed in CA1 (Fig. 3 and Fig. 4).
Interestingly, it is not just the timing that varies, but also the
morphology of aggregate formation. Htt aggregates in DG
neurons had a more punctate morphology than those first seen
in CA1 cells (Fig. 3), and they continued to grow with time (Fig. 4)
until they reached the stage where MW8-stained aggregates were
of similar appearance to the nucleation centres described by Chen
et al., [41]. By contrast, aggregates in cortical neurons were similar
to those that formed in CA1 neurons, beginning as diffuse deposits
in nuclei and then clustered into MW8-positive aggregates with
nucleated centres.
Aggregate Formation in different Brain Regions is
Differentially, but Precisely, Timed
There was a defined and consistent order to the organisation
and timing of first appearance of Htt aggregates in R6/2 brains.
As mentioned above, in the IG Htt aggregates were already
present at 14 days of age (Fig. 1). Subsequently, Htt aggregates
appeared (by 19 days of age), in the CA1 region of the Hf (Fig. 4)
and the deeper layers of parietal, frontal and cingulate CTX.
Aggregates also began to form in cells in layer II/III of parietal
CTX (but not other parts of the CTX) at this time (Fig. 2).
Between 19 and 22 days, aggregates in IG and CA1 grew larger
(Fig. 3). By 22 days, almost all (.80%) cells in the deep layers of
parietal CTX had visible aggregates that were MW8-positive
(Fig. 2). Over the following few days marked increases in aggregate
size and frequency of appearance in brain regions already
containing aggregates were observed, while Htt aggregates just
began to form in the DG and in STR by 26 days (Fig. 4). Finally,
Figure 2. Aggregate appearance in parietal cortex (CTX). Htt aggregates visualised by staining with the MW8 antibody were present in the
CTX of R6/2 brains at 16 days in layer V (E, F; black arrowheads) and at 18 days in layer II/III (C, black arrowheads). Staining with ubiquitin antibody did
not reveal the presence of inclusions in any region at these time points (A’–F’). Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g002
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CA3 neurones began to form visible Htt-positive aggregates by 29
days (Fig. 4). By 41 days, the majority of cells contained aggregates
of Htt protein in dense nuclear foci (Fig. 4). The exceptions were
DG and CA3 cells, in which progression of aggregate formation
was much slower.
Htt Aggregation Precedes Ubiquitination
In all R6/2 brain regions studied, the appearance of Htt-
positive aggregates preceded inclusion ubiquitination. At 14 days
of age, there were no ubiquitinated inclusions in any brain region,
which reproduces previous observations that no NIIs could be
found in any brain regions of R6/2 mice at that age [25,42]. The
appearance of ubiquitinated inclusions occurred first in the IG by
19 days (Fig. 5). Ubiquitinated inclusions in other brain regions
were observed at 24 days, when neurones in the CA1 region of the
Hf began to show round amorphous ubiquitin-stained inclusions
(Fig. 5). Over the next few days, there was a marked increase in the
size and frequency of ubiquitinated inclusions in the IG as well as
CA1. By 26 days, many IG and CA1 aggregates were
ubiquitinated (Fig. 5). By 29 days, although Htt aggregates were
present in neurons of the STR, DG and CA3 of the Hf, none of
them were ubiquitinated (Fig. 5). At 41 days (nearly 6 weeks),
Figure 3. Aggregate appearance in CA1 and dentate gyrus (DG). In R6/2 hippocampus, Htt aggregates visualised by staining with the MW8
antibody could not be seen at 18 days of age but could be found in many neurons at 19 days in the CA1 (B, black arrowheads) and increased in
number with time (C, black arrowheads). Cell distribution in this region is shown in a parallel section showed with a cresyl violet stain (A’’–C’’). In the
DG, MW8-positive aggregates were absent up to 24 days, but were present at 26 days (F, black arrowheads). Staining with ubiquitin antibody did not
reveal the presence of inclusions in any region at these time points (A’–F’). Cell distribution in both regions was visualised with a cresyl violet (CV)
stain (D’’–F’’). Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g003
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aggregates in many brain regions were ubiqutinated, and
continued to grow bigger, as seen previously [25]. They appeared
to have reached a stable density in the IG and in CA1 (Fig. 5). In
addition, by that age, ubiquitinated aggregates were present in the
CA3. The only brain region in which cells did not have
ubiqutinated inclusions by 41 days of age was the DG (Fig. 5).
These observations are generally consistent with previous studies,
where ubiqutinated NIIs were seen in DG only at 7 weeks of age
and beyond [25]. By 63 days (9 weeks), when all neurones studied
had aggregates (see Fig. 5), most were mature, ubiquitinated
inclusions.
Patterns of Ubiquitination Depend on Cell Soma Size
Previous observations have shown that increases in NII size are
not due to increases in the sizes of nuclei [25], however the timing
of initial aggregation formation with regard to the sizes of nuclei
has not been studied until now. Here we compared cells in specific
brain regions to see if a relationship existed between cell soma size,
the propensity to form Htt aggregates and the time-course of
ubiquitination. Neurons were classified as having small, medium
or large soma. Granule cells of the DG were classified as ‘small’,
CA1 pyramidal neurons and medium spiny striatal neurons were
classified as ‘medium-sized’ and CA3 and cortical pyramidal
neurons were classified as having ‘large’ soma. A direct
comparison of MW8 staining patterns in cells from these brain
regions showed that there was no correlation between the timing
of aggregate formation and cell soma size (Fig. 6). For example,
cells with medium-sized soma can form Htt aggregates as early as
22 days (CA1 neurons) or as late as 28 days of age (STR neurons).
Likewise, cells with large soma can form aggregates as early as 19
days (neurons in parietal CTX) or as late as 28 days of age (CA3
neurons) (Fig. 6). However, timing of ubiquitination appeared to
be related to cell soma size. Regardless of whether or not
huntingtin aggregates formed early or late, aggregates that formed
in cells with small and medium-sized soma were found
ubiquitinated within 2–3 days of initial aggregation (Fig. 6). By
contrast, there was usually lag of.3 days between initial aggregate
formation and inclusion ubiquitination in cells with large soma
(Fig. 6). For example, although aggregates formed early in cortical
cells (19 days), ubiquitinated inclusions did not typically appear
until after 22 days. In CA3 neurons, although Htt aggregates
appeared by 29 days (Fig. 6), not all aggregates had been
ubiquitinated before the end of the period over which we
conducted 24-hour interval time-course study (that is, in CA3
neurons, some aggregates were ubiquitinated later than 41 days).
Structural Investigation of Aggregate and Inclusion
Formation
In order to compare MW8 and ubiquitin staining patterns in
single R6/2 neurons in the brain regions and at the time-points
Figure 4. Aggregate appearance in different brain regions over time. Htt aggregates visualised by staining with the MW8 antibody (shown
here at 14, 19, 22, 24, 26, 29, 41 and 63 days) in indisium griseum (IG), CA1, CA3, dentate gyrus (DG) and dorso-medial and ventro-lateral striatum (STR
DM and STR VL) of R6/2 brains. A few aggregates were visualised in the IG as early as 14 days of age. In the hippocampus, inclusions were present at
19 days in CA1, whereas in the CA3 a few aggregates were visible at 29 days of age. In the dentate gyrus, MW8-positive aggregates were present at
26 days. In the striatum, Htt aggregates could be seen at 26 days of age in STR DM and STR VL. The number of aggregates in all the regions increased
with time from the day of appearance. Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g004
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studied in Figure 4, we used high magnification microscopy
analysis. The initial morphology of MW8-positive aggregates were
different from ubiquitin-positive inclusions, in that only nucleation
centres of Htt aggregates were ubiquitinated (Fig. 7). Interestingly,
MW8-immunolabelled Htt protein associated with the aggregate
but not localised to the nucleation centre was not ubiquitinated
(Fig. 7). It is possible that antigen sites on protein in parts of the
aggregates may be masked by other proteins, but this seems
unlikely, since the dense aggregate cores/nucleation centres were
immunolabelled. It seems more likely that the MW8 antibody was
labelling both aggregated and aggregating Htt, whereas ubiquitin
labelled only Htt that was already aggregated. It is also notable
that we could observe MW8-labelled cells before any aggregates
were visible supporting the idea that there is an oligomerisation of
Htt before visible aggregates form [43,44,45]. Again, this was not
seen with ubiquitin staining, supporting our suggestion that the
protein was not ubiquitinated before it aggregated.
By 41 days, neurons reach their developmental end-stage,
there was complete overlap between MW8 and ubiquitin
immonolabelling (Fig. 7), with ubiquitinated inclusion very
similar to that of MW8-positive aggregates in all regions apart
from CA3 neurons. Note, the precise timing of ubiquitination
was not determined in the case of inclusions in CA3 neurons,
because the aggregates in these cells develop later than in other
regions. Htt aggregates are present in CA3 by 29 days of age,
but the MW8 staining pattern in CA3 neurons was in-
distinguishable from the ubiquitin pattern, with regard to size
and morphology, only by 63 days (Fig. 7).
The only region in which the staining pattern was different from
that of Hf and CTX was the STR. In the STR, aggregates with
clear nucleation centres appeared at around 25 days (Fig. 7).
However, there was no lag in the appearance of ubiquitin-labelled
inclusions, which were present in STR neurones at the same time
(Fig. 7) and not at around 41 days (Fig. 5, 6). In contrast to what
was seen in other regions, the ubiquitinated inclusions in the STR
appeared to be much larger than the MW8-positive aggregates.
We suggest that these aggregates formed a core or nucleation
centre of Htt surrounded by ubiquitinated proteins that were not
MW8-positive. While the size of the Htt-positive aggregates in the
STR grew with time, the ubiquitinated inclusions did not appear
to change much in size (Fig. 7), and the ubiquitinated inclusions
remained larger than the Htt nucleation centres for several weeks.
MW8-positive aggregate growth continued in the STR until 63
days, by which time STR inclusions appeared to have reached
a stable state, and there was no longer an obvious morphological
difference between the MW8-immunolabelled aggregates and the
ubiquitin-labelled inclusions (Fig. 7).
Discussion
Htt aggregates have not been reported in R6/2 brains before 3
weeks of age. Here, we have been able to capture an earlier time
Figure 5. Inclusion appearance in different brain regions over time. Ubiquitinated Htt aggregates visualised by staining with the ubiquitin
antibody (shown here at 14, 19, 22, 24, 26, 29, 41 and 63 days) in IG, CA1, CA3, DG and STR of R6/2 brains. A few inclusions are visible in the IG at 19
days of age. In the hippocampus, aggregates were present at 24 days in CA1, whereas in the CA3 a few aggregates were visible at 41 days of age. In
the DG, a few ubiquitin-positive inclusions were present at 41 days. In the striatum, inclusions could be setected at 41 days of age in STR DM and STR
VL. The number of aggregates in all the regions increased with time from the day of appearance. Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g005
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course of aggregate formation earlier than has been shown
previously. We find that aggregates are already present in R6/2
brain by 2 weeks of age. Thus, visible mutant Htt aggregation in
immature R6/2 brain appears at a time much earlier than
previously thought. Even though it is only a week earlier than
previously reported, this is likely to be important as the first 2–3
weeks of life in a mouse is the critical time for brain and synaptic
development, and cells are particularly vulnerable to excitotoxic
insults in the immediate postnatal period [46]. Furthermore, and
in contrast to other studies where ubiquitinated inclusions are
considered to be indistinguishable from Htt-positive inclusions, we
show a dissociation in the pattern of aggregate formation as shown
by MW8- or ubiquitin staining. From our data we conclude that
the pattern of aggregation of mutant Htt is not first recognised as
foreign/abnormal, ubiquitinated, and then targeted to the
proteasome where aggregation occurs, but rather that the proteins
aggregate and then ubiquitination occurs (or ubiquitinated protein
is recruited to the aggregates).
We showed previously that inclusions form in juvenile R6/2
brain in distinct phases that consist of (i) precipitation of
aggregation centres, (ii) growth of inclusions and (iii) formation
of extranuclear neuronal inclusions (ENNIs) [25]. Our previous
investigations focused solely on ubiquitinated inclusions, which
appear precipitously at around 3 weeks. A more recent
immunostaining study of inclusion formation in R6/2 brains
showed similar results, with identical overlapping patterns of
inclusion labelling using EM48 and ubiquitin antibodies [42]. Our
results generally agree with these of Meade et al., [42] and support
the present model of aggregate formation in which nucleation
centres seed further aggregation of mutant proteins [41].
However, the EM48 staining done by Meade et al. failed to label
any aggregates that were not ubiquitinated at any point in the
time-course, and they describe the two immunostaining patterns as
identical [42]. This discrepancy might be due to the fact that
although both MW8 and EM48 bind to epitopes of the C-ter
region, MW8 selectively binds aggregated Htt and is therefore
more selective to the mutant form of the protein [38,47].
Aggregate Formation is a Very Rapid Event that is
Differentially Timed According to Brain Region
Most prior studies, including our own, have never observed the
rapidity with which the early events occur. This is because in most
studies tissue is collected at weekly or even monthly intervals. Our
tissue collection protocol allowed us to see changes that happened
within 24 hours. We found that in vivo, visible aggregate formation
is rapid, occurring within 24 hours. Interestingly, this parallels the
situation we observed earlier with aggregation in tissue culture,
where inclusions typically take 15–30 hours to form [22]. Protein
aggregation has been described as a nucleation-dependent process
[48]. Nucleated growth polymerization starts with the energeti-
cally unfavourable formation of a nucleus (i.e., nucleation),
followed by efficient elongation of the nucleus via sequential
additions of monomers [49,50]. In spite of the fact that nucleation
is considered to be a slow process, and has been shown to be
roughly 1,000 times slower in the cell than in vitro [51]. However,
we show here that in most of the cells, Htt aggregates (visualised
with MW8) appeared almost overnight.
Aggregates Develop Late in the Striatum
In addition to being precisely timed, aggregate formation was
found to be brain region-dependent. Aggregates formed first in the
IG, then in the CA1, subsequently in the CTX, followed by STR
and finally in the DG and CA3. It is not clear what determines the
pattern of aggregate formation, but it is unlikely to be correlated
with neuronal vulnerability [52]. Nor does it relate to the putative
vulnerability of neurons, since compared to the cortex and
hippocampus, the appearance of aggregate formation in the STR,
the region most affected by neurodegeneration in HD [52,53],
lagged behind that in other regions. There are of course a number
Figure 6. The timing of ubiquitination is dependent of cell soma size in R6/2 neurons. Regardless of whether or not huntingtin aggregates
(visualized by staining with MW8 and ubiquitin antibodies) formed early or late, aggregates that formed in cells with small (DG neurons) and
medium-sized (CA1 and STR) soma were found ubiquitinated within 2 to 3 days of initial aggregation. By contrast, there was typically a more than 3
days lag between initial aggregate formation and inclusion ubiquitination in cells with large soma (CA3). Scale bar = 50 mm.
doi:10.1371/journal.pone.0041450.g006
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of different consequences of late development of aggregates in the
striatum. If the aggregates are toxic, the early aggregate formation
in cortical neurons could result in abnormal synaptic input to the
striatum. There is ample and elegant evidence for early
corticostriatal dysfunction in R6/2 mice [54,55,56,57]. On the
other hand, if the aggregates are protective, the fact that
aggregation of Htt in the striatal cells is delayed may make them
more vulnerable to the toxicity of non-aggregated Htt [17]. Why
there is such a big difference in the time-course of aggregation in
the striatum compared the rest of the brain is also of particular
interest, given that the striatum is most vulnerable to neurode-
generation. It is not possible to determine neuronal function or
dysfunction from histopathological observations. In our opinion, it
is likely that aggregate formation has complex downstream
consequences that may be both beneficial and deleterious
depending on the time and age of the animals [22,25].
It is important to stress that all transgenic mouse models of HD
develop neuronal inclusions. In R6/2 mice NIIs develop prior to
the onset of neurological symptoms [2,7]. By contrast, in N171-
82Q and in YAC128 mice NIIs appear after the symptoms
[58,59]. Finally in BACHHD mice inclusions are mainly (.90%)
extranuclear [60]. Interestingly, the presence of aggregates is not
more prevalent in neuronal subpopulations known to die earliest
in HD, nor does it seem to correlate to neuronal death
[16,17,59,60]. Therefore, despite studies suggesting a causal
relationship, it is still not clear if aggregates play an active role
in HD pathogenesis, or if they are simply markers of pathology.
More studies about aggregate formation are needed.
Ubiquitination Occurs after Aggregate Formation
Our results agree with those of Meade et al., where no
ubiquitinated inclusions were found at all in CTX at 2 weeks
(but were present in all layers by 3.5 weeks). We found that the
time that elapsed between Htt aggregation and inclusion
ubiquitination was dependent of the soma size, with a longer lag
between initial aggregate formation and ubiquitination for large
cells.
Our results support previous observations that ubiquitin
associates at a relatively late stage in the maturation of aggregates
into inclusions [62,63]. Although we [30] and several other groups
have reported occasional aggregates [2,16,61] and microaggre-
gates [16,61] that were not ubiquitinated, none of these have
examined this in detail, and none have used tissue taken from sort
interval timecourses that would allow a detailed study of this
observation. In our previous study [30] we used PC12 cells to track
aggregate morphology using time-lapse microscopy. We found
clear evidence for aggregates that were not ubiquitinated at early
stages of formation. Nevertheless, it was not clear if this
phenomenon would be observed in brain tissue as well as
immortalized cell lines. We have now shown that this appears to
be present in the brain of R6/2 mice.
Given the early timing of the events we have reported (when
aggregates are just beginning to appear), and the fact that we
did not see aggregates that were partially ubiquitinated, we have
interpreted our data as being due to the fact that ubiquitination
of the protein in the aggregates has not yet occurred, or if it
has, it is not enough to be visualised. It should be noted
however that the presence of non-ubiquitinated aggregates could
be due to de-ubiquitination of mutant htt. This is an interesting
possibility, although testing it is beyond the scope of the current
study, since the dynamics of ubiquitination/de-ubuqitination
cannot be measured in post mortem tissue. Since there was little
to no increase in background ubiquitin staining with the
appearance of inclusions, in contrast to the increase in
background expression of MW8-positive staining (data not
shown), the most parsimonious explanation for our data is that
monomeric mutant Htt is not recognised as ‘toxic’ until
aggregation has started. We cannot rule out the possibility that
soluble Htt might be ubiquitinated. However, in the R6/2 mice
there is only normal full length Htt, so it seems unlikely that it
will contribute to the pathological process at the earliest stages
of aggregate formation.
We do not know the reason for the ubiquitination. It is possible
that it is only after Htt has started to aggregate that it is recognised
as foreign and ubiquitinated. However, importantly, to our
knowledge, it has never been shown directly that mutant Htt is
ubiquitinated. It has been assumed that mutant huntingtin is
ubiquitinated and targeted for degradation by the ubiquitin-
proteasome system pathway, because mutant huntingtin is an
abnormal moiety found in neuronal intranuclear inclusions,
neuronal nuclear inclusions are ubiquitinated and proteasome
fragments are associated with NIIs. The possibility that mutant Htt
is not recognised as foreign is consistent with the late onset of the
disease in humans, where there is very little pathology for 30–40
years in the case of most adults, despite expression from both
alleles [64,65,66,67,68,69]. Another possible explanation for our
finding is that ubiquitin does not label mutant Htt but labels other
proteins whose recruitment and inactivation trigger detrimental
effects. Mutant Htt is known to recruit WT Htt via its
polyglutamine tract, and normal Htt has been found to associate
with an ubiquitin-conjugating enzyme (hE2-25K) in a manner that
is not modulated by the length of the polyglutamine stretch [70].
Since normal Htt is larger and has more ubiquitination sites than
the mutant fragments expressed in R6/2 brain [71]. It is possible
that the normal Htt, rather than mutant Htt, may be the target of
ubiquitination in R6/2 brain. It is also possible that proteins other
than Htt containing a poly(Gln) sequence are ubiquitinated and
recruited during aggregate formation [72,73,74,75,76].
Conclusion
Our results show for the first time that Htt aggregation in mouse
brain is not only an early event, but that it occurs rapidly.
Furthermore, ubiquitination is temporally dissociated from Htt
aggregation. Both the timing of inclusion formation and the
cellular recognition of the mutant protein as toxic are likely to be
important events in HD pathology. The aggregation events we
describe appear very early in R6/2 brain, well before any obvious
detectable neurological phenotype. The onset of symptoms may
signal a change in the role of aggregates from cytoprotective, to
neurotoxic.
Figure 7. Comparison of MW8 and ubiquitin staining patterns. Higher magnification microscopy analysis was used in order to compare MW8
and ubiquitin staining patterns in single R6/2 neurons. In CA1, CA3 and cortex, MW8 labelling could be observed in cells before any aggregates were
visible, a phenomenon that was not apparent with ubiquitin staining. The initial morphologies of MW8-positive aggregates were different from
ubiquitin-positive inclusions, in that only nucleation centres of the aggregates were ubiquitinated and the MW8-immunolabelled Htt protein that was
not localised to the nucleation centre did not appear to be ubiquitinated. In contrast, aggregates with clear nucleation centres were visible by 25
days in the striatum. And at the same time, larger punctate ubiquitin-labelled inclusions were already visible in STR neurones. Ubiquitinated
inclusions were much bigger than MW8-positive aggregates and did not change much in size, even though Htt aggregates got bigger with time.
doi:10.1371/journal.pone.0041450.g007
Aggregation Precedes Ubiquitination in R6/2 Mice
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e41450
There are many controversial theories about pathological
mechanisms in HD and their link with inclusion formation.
However, Htt aggregation precedes symptoms in patients and
mouse models. Therefore, characterizing the early stages of
aggregate formation in mouse models are important steps that
may help us understand the relationship between inclusion
formation and mechanisms underlying cell death in HD.
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